Πλοήγηση ανά Συγγραφέα "Akriviadis, E."

Αποτελέσματα 1-4 από 4

HBSAG LEVELS DECLINE > 10% DURING 48 WEEKS OF PEGINTERFERON ALFA-2A 40KD (PEGASYS) TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITS B (CHB) FAVORS END OF TREATMENT RESPONSE: PRELIMINARY ANALYSIS OF THE PERSEAS COHORT

Goulis, L.; Akriviadis, E.; Karatapanis, S.; Deutsch, M.; Dalekos, G. N.; Raptopoulou-Gigi, M. P.; Drakoulis, C.; Mimidis, K.; Germanidis, G.; Nikolopoulou, V.; Chounta, A.; Bakalos, G.; Papatheodoridis, G. V. (2011)
HBSAG LEVELS DECLINE DURING PEGINTERFERON ALFA-2A 40KD (PEGASYS) TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B FAVORS 6 MONTHS POST-TREATMENT RESPONSE: PERSEAS COHORT INTERIM ANALYSIS

Goulis, I.; Akriviadis, E.; Karatapanis, S.; Deutsch, M.; Dalekos, G.; Raptopoulou-Gigi, M.; Mimidis, K.; Germanidis, G.; Triantos, C.; Drakoulis, C.; Chounta, A.; Tsoplou, F.; Zintzaras, E.; Bakalos, G.; Papatheodoridis, G. (2012)
HBSAG LEVELS DURING THE FIRST 24 WEEKS OF PEGINTERFERON ALFA-2A 40KD (PEGASYS) TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B: THE PERSEAS COHORT

Goulis, I.; Akriviadis, E.; Karatapanis, S.; Deutsch, M.; Dalekos, G.; Raptopoulou-Gigi, M.; Drakoulis, C.; Bakalos, G.; Papatheodoridis, G. (2011)
On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients

Goulis, I.; Karatapanis, S.; Akriviadis, E.; Deutsch, M.; Dalekos, G. N.; Raptopoulou-Gigi, M.; Mimidis, K.; Germanidis, G.; Drakoulis, C.; Triantos, C.; Zintzaras, E.; Bakalos, G.; Papatheodoridis, G. (2015)

Background & AimsWe assessed predictors of response in HBeAg-negative chronic hepatitis B patients treated with peginterferon alfa-2a in routine clinical practice. MethodsNinety-five HBeAg-negative patients received ...

Πλοήγηση ανά Συγγραφέα "Akriviadis, E."

HBSAG LEVELS DECLINE > 10% DURING 48 WEEKS OF PEGINTERFERON ALFA-2A 40KD (PEGASYS) TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITS B (CHB) FAVORS END OF TREATMENT RESPONSE: PRELIMINARY ANALYSIS OF THE PERSEAS COHORT ﻿

HBSAG LEVELS DECLINE DURING PEGINTERFERON ALFA-2A 40KD (PEGASYS) TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B FAVORS 6 MONTHS POST-TREATMENT RESPONSE: PERSEAS COHORT INTERIM ANALYSIS ﻿

HBSAG LEVELS DURING THE FIRST 24 WEEKS OF PEGINTERFERON ALFA-2A 40KD (PEGASYS) TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B: THE PERSEAS COHORT ﻿

On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients ﻿

HBSAG LEVELS DECLINE > 10% DURING 48 WEEKS OF PEGINTERFERON ALFA-2A 40KD (PEGASYS) TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITS B (CHB) FAVORS END OF TREATMENT RESPONSE: PRELIMINARY ANALYSIS OF THE PERSEAS COHORT

HBSAG LEVELS DECLINE DURING PEGINTERFERON ALFA-2A 40KD (PEGASYS) TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B FAVORS 6 MONTHS POST-TREATMENT RESPONSE: PERSEAS COHORT INTERIM ANALYSIS

HBSAG LEVELS DURING THE FIRST 24 WEEKS OF PEGINTERFERON ALFA-2A 40KD (PEGASYS) TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B: THE PERSEAS COHORT

On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients